The EAP study in patients (n=140) with SR/SD GI-aGvHD showed a GI-ORR of 52% at D28, OS of 54%, 47% & 42% at 6mos., 12mos. & 18mos., respectively, with 28% achieving CR. OS was greater with 68% vs 24% at 12mos. & 58 vs 24% at 18mos. in MaaT013 responders vs non-responders
Among a subset of patients (n=49) refractory to steroids & ruxolitinib, GI-ORR was 63% at D28 with 49% achieving CR, OS rates were 52%, 49% & 42% at 6mos., 12mos. & 18mos., respectively, & overall ORR was 61% with 43% CR. OS was greater with 76% vs 6% at 12mos. & 64% vs 6% at 18mos. in MaaT013 responders vs non-responders
To confirm the EAP data, MaaT013 is being assessed in the P-III (ARES) trial among corticosteroid & ruxolitinib-refractory GI-aGvHD patients
Ref: MaaT Pharma | Image: MaaT Pharma
Related News:- MaaT Pharma Receives Positive Opinion from DSMB for MaaT013 in P-III Trial to Treat Graft Versus Host Disease (GvHD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
